Dionex to purchase ESA Biosciences’ HPLC portfolio

Friday, 25 September, 2009

Dionex has entered into an asset purchase agreement with ESA Biosciences, a wholly owned subsidiary of Magellan Biosciences, to purchase ESA Biosciences’ HPLC-related products, HPLC clinical assays, laboratory services and assets.

This acquisition will add three HPLC detector families to the Dionex HPLC product portfolio:

  • Corona Family of Universal Charged Aerosol Detectors (CAD) is the ‘universal’ HPLC detector targeting pharmaceutical and biopharmaceutical development, manufacturing and QA/QC processes.
  • CoulArray and Coulochem detectors are electrochemical detectors targeting neuroscience, clinical, and metabolomics research applications.

Combined with Dionex expertise in electrochemistry detection for carbohydrates and glycobiology, this acquisition will position Dionex as the leading provider of comprehensive electrochemistry solutions for liquid chromatography.

Related News

AI.gov.au launches to help safe and responsible AI use

Providing guidance, tools and resources to help Australian businesses use AI safely, the...

AusBiotech responds to Budget 2026–27

The life sciences industry body has responded to measures set out in the Australian...

$6.2m for nine science projects involving Japan and neighbours

Investments under the Global Science and Technology Diplomacy Fund will support nine...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd